The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
The genesis and evolution of high-grade serous ovarian cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Stewart, B. W., & Kleihues, P. (2003) · Cited by 2,386
International network of cancer genome projects
The International Cancer Genome Consortium (2010) · Nature · doi:10.1038/nature08987 · Cited by 2,299
Cancer as an evolutionary and ecological process
Merlo, L. M. F., Pepper, J. W., Reid, B. J., & Maley, C. C. (2006) · Nature Reviews Cancer · doi:10.1038/nrc2013 · Cited by 1,699
Hallmarks of 'BRCAness' in sporadic cancers
Turner, N., Tutt, A., & Ashworth, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1457 · Cited by 1,657
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
Tothill, R. W., Tinker, A. V., George, J., Brown, R., Fox, S. B., Lade, S., Johnson, D. S., Trivett, M. K., Etemadmoghadam, D., Locandro, B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0196 · Cited by 1,467
Self-citationGenome-wide analysis of DNA copy-number changes using cDNA microarrays
Pollack, J. R., Perou, C. M., Alizadeh, A. A., Eisen, M. B., Pergamenschikov, A., Williams, C. F., Jeffrey, S. S., Botstein, D., & Brown, P. O. (1999) · Nature Genetics · doi:10.1038/12640 · Cited by 1,423
The biology of ovarian cancer: new opportunities for translation
Bast, R. C., Hennessy, B., & Mills, G. B. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2644 · Cited by 1,358
Kindelberger, D. W., Lee, Y., Miron, A., Hirsch, M. S., Feltmate, C., Medeiros, F., Callahan, M. J., Garner, E. O., Gordon, R. W., Birch, C., et al. (2007) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213335.40358.47 · Cited by 1,113
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Sakai, W., Swisher, E. M., Karlan, B. Y., Agarwal, M. K., Higgins, J., Friedman, C., Villegas, E., Jacquemont, C., Farrugia, D. J., Couch, F. J., et al. (2008) · Nature · doi:10.1038/nature06633 · Cited by 1,086
Resistance to therapy caused by intragenic deletion in BRCA2
Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., Boyd, J., Reis-Filho, J. S., & Ashworth, A. (2008) · Nature · doi:10.1038/nature06548 · Cited by 1,011
Fong, P. C., Yap, T. A., Boss, D. S., Carden, C. P., Mergui-Roelvink, M., Gourley, C., De Greve, J., Lubinski, J., Shanley, S., Messiou, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9589 · Cited by 1,010
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
Silver, D. P., Richardson, A. L., Eklund, A. C., Wang, Z. C., Szallasi, Z., Li, Q., Juul, N., Leong, C.-O., Calogrias, D., Buraimoh, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4725 · Cited by 981
MYC as a regulator of ribosome biogenesis and protein synthesis
van Riggelen, J., Yetil, A., & Felsher, D. W. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2819 · Cited by 956
A candidate precursor to serous carcinoma that originates in the distal fallopian tube
Lee, Y., Miron, A., Drapkin, R., Nucci, M., Medeiros, F., Saleemuddin, A., Garber, J., Birch, C., Mou, H., Gordon, R., et al. (2007) · The Journal of Pathology · doi:10.1002/path.2091 · Cited by 898
Complex landscapes of somatic rearrangement in human breast cancer genomes
Stephens, P. J., McBride, D. J., Lin, M.-L., Varela, I., Pleasance, E. D., Simpson, J. T., Stebbings, L. A., Leroy, C., Edkins, S., Mudie, L. J., et al. (2009) · Nature · doi:10.1038/nature08645 · Cited by 845
Xu, X., Weaver, Z., Linke, S. P., Li, C., Gotay, J., Wang, X.-W., Harris, C. C., Ried, T., & Deng, C.-X. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80466-9 · Cited by 819
Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies
Köbel, M., Kalloger, S. E., Boyd, N., McKinney, S., Mehl, E., Palmer, C., Leung, S., Bowen, N. J., Ionescu, D. N., Rajput, A., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050232 · Cited by 814
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
Ahmed, A. A., Etemadmoghadam, D., Temple, J., Lynch, A. G., Riad, M., Sharma, R., Stewart, C., Fereday, S., Caldas, C., deFazio, A., et al. (2010) · The Journal of Pathology · doi:10.1002/path.2696 · Cited by 787
Self-citationDeregulated cyclin E induces chromosome instability
Spruck, C. H., Won, K.-A., & Reed, S. I. (1999) · Nature · doi:10.1038/45836 · Cited by 692
Risch, H. A., McLaughlin, J. R., Cole, D. E. C., Rosen, B., Bradley, L., Fan, I., Tang, J., Li, S., Zhang, S., Shaw, P. A., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj465 · Cited by 680
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
Mendes‐Pereira, A. M., Martin, S. A., Brough, R., McCarthy, A., Taylor, J. R., Kim, J., Waldman, T., Lord, C. J., & Ashworth, A. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900041 · Cited by 638
Involvement of Brca2 in DNA Repair
Patel, K. J., Yu, V. P. C. C., Lee, H., Corcoran, A., Thistlethwaite, F. C., Evans, M. J., Colledge, W. H., Friedman, L. S., Ponder, B. A. J., & Venkitaraman, A. R. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80035-0 · Cited by 634
Vang, R., Shih, I.-M., & Kurman, R. J. (2009) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e3181b4fffa · Cited by 562
Secondary BRCA1 Mutations in BRCA1 -Mutated Ovarian Carcinomas with Platinum Resistance
Swisher, E. M., Sakai, W., Karlan, B. Y., Wurz, K., Urban, N., & Taniguchi, T. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0088 · Cited by 457
EMSY Links the BRCA2 Pathway to Sporadic Breast and Ovarian Cancer
Hughes-Davies, L., Huntsman, D., Ruas, M., Fuks, F., Bye, J., Chin, S.-F., Milner, J., Brown, L. A., Hsu, F., Gilks, B., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00930-9 · Cited by 421
Zorn, K. K., Bonome, T., Gangi, L., Chandramouli, G. V. R., Awtrey, C. S., Gardner, G. J., Barrett, J. C., Boyd, J., & Birrer, M. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0508 · Cited by 376
Histopathologic Grading of Ovarian Carcinoma: A Review and Proposal
Silverberg, S. G. (2000) · International Journal of Gynecological Pathology · doi:10.1097/00004347-200001000-00003 · Cited by 351
Lessons from BRCA: the Tubal Fimbria Emerges as an Origin for Pelvic Serous Cancer
Crum, C. P., Drapkin, R., Kindelberger, D., Medeiros, F., Miron, A., & Lee, Y. (2007) · Clinical Medicine & Research · doi:10.3121/cmr.2007.702 · Cited by 342
Marquez, R. T., Baggerly, K. A., Patterson, A. P., Liu, J., Broaddus, R., Frumovitz, M., Atkinson, E. N., Smith, D. I., Hartmann, L., Fishman, D., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2509 · Cited by 308
Etemadmoghadam, D., deFazio, A., Beroukhim, R., Mermel, C., George, J., Getz, G., Tothill, R., Okamoto, A., Raeder, M. B., AOCS Study Group, et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1564 · Cited by 302
Self-citationLee, K. R., & Young, R. H. (2003) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200303000-00001 · Cited by 293
Folkins, A. K., Jarboe, E. A., Saleemuddin, A., Lee, Y., Callahan, M. J., Drapkin, R., Garber, J. E., Muto, M. G., Tworoger, S., & Crum, C. P. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.01.012 · Cited by 293
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities
Press, J. Z., De Luca, A., Boyd, N., Young, S., Troussard, A., Ridge, Y., Kaurah, P., Kalloger, S. E., Blood, K. A., Smith, M., et al. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-17 · Cited by 287
Gene Expression Profiles of BRCA1-Linked, BRCA2-Linked, and Sporadic Ovarian Cancers
Jazaeri, A. A., Yee, C. J., Sotiriou, C., Brantley, K. R., Boyd, J., & Liu, E. T. (2002) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/94.13.990 · Cited by 282
Lee, H., Trainer, A. H., Friedman, L. S., Thistlethwaite, F. C., Evans, M. J., Ponder, B. A. J., & Venkitaraman, A. R. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80182-3 · Cited by 234
Inactivation of BRCA1 and BRCA2 in Ovarian Cancer
Hilton, J. L. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.18.1396 · Cited by 218
Levanon, K., Ng, V, Piao, H. Y., Zhang, Y., Chang, M. C., Roh, M. H., Kindelberger, D. W., Hirsch, M. S., Crum, C. P., Marto, J. A., et al. (2010) · Oncogene · doi:10.1038/onc.2009.402 · Cited by 214
Linking the Cellular Functions of BRCA Genes to Cancer Pathogenesis and Treatment
Venkitaraman, A. R. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.3.121806.151422 · Cited by 203
Collins, F. S., & Barker, A. D. (2007) · Scientific American · doi:10.1038/scientificamerican0307-50 · Cited by 197
Collins, F. S., & Barker, A. D. (2007) · PubMed · Cited by 176
High Incidence of Protein-Truncating TP53 Mutations in BRCA1-Related Breast Cancer
Holstege, H., Joosse, S. A., van Oostrom, C. T. M., Nederlof, P. M., de Vries, A., & Jonkers, J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3426 · Cited by 171
Schwartz, D. R., WU, R. T., Kardia, S. L. R., Levin, A. M., Huang, C.-C., Shedden, K., Kuick, R. D., Misek, D. E., Hanash, S., Taylor, J. M. G., et al. (2003) · PubMed · Cited by 170
Tiling Path Genomic Profiling of Grade 3 Invasive Ductal Breast Cancers
Natrajan, R., Lambros, M. B., Rodríguez-Pinilla, S. M., Moreno-Bueno, G., Tan, D. S. P., Marchió, C., Vatcheva, R., Rayter, S., Mahler-Araujo, B., Fulford, L. G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1878 · Cited by 170
Birrer, M., Johnson, M. E., Hao, K., Wong, K. K., Park, D., Bell, A., Welch, W., Berkowitz, R., & Mok, S. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.0795 · Cited by 165
Manié, É., Vincent‐Salomon, A., Lehmann‐Che, J., Pierron, G., Turpin, E., Warcoin, M., Gruel, N., Lebigot, I., Sastre‐Garau, X., Lidereau, R., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-1560 · Cited by 163
Tone, A. A., Begley, H., Sharma, M., Murphy, J., Rosen, B. P., Brown, T. J., & Shaw, P. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4959 · Cited by 153
Advances in the Recognition of Tubal Intraepithelial Carcinoma
Lee, Y., Medeiros, F., Kindelberger, D. W., et al. (2006) · Advances in Anatomic Pathology · doi:10.1097/01.pap.0000201826.46978.e5 · Cited by 152
Frequency of BRCA1 Dysfunction in Ovarian Cancer
Geisler, J. P. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.1.61 · Cited by 141
Colorectal Cancer: A Multipathway Disease
Jass, J. R. (2006) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v12.i3-4.50 · Cited by 123
A mouse model for cyclin E-dependent genetic instability and tumorigenesis
Loeb, K. R., Kostner, H., Firpo, E. J., Norwood, T. H., Tsuchiya, K. D., Clurman, B. E., & Roberts, J. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.06.010 · Cited by 111
Norquist, B. M., Garcia, R. L., Allison, K. H., Jokinen, C. H., Kernochan, L. E., Pizzi, C. C., Barrow, B. J., Goff, B. A., & Swisher, E. M. (2010) · Cancer · doi:10.1002/cncr.25439 · Cited by 108
Gelmon, K. A., Hirte, H. W., Robidoux, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3002 · Cited by 103
Haverty, P. M., Hon, L., Kaminker, J. S., Chant, J., & Zhang, Z. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-21 · Cited by 96
DNA Methylome of Familial Breast Cancer Identifies Distinct Profiles Defined by Mutation Status
Flanagan, J. M., Cocciardi, S., Waddell, N., Johnstone, C. N., Marsh, A. J., Henderson, S. R., Simpson, P. T., Silva, L. M. D., Khanna, K. K., Lakhani, S. R., et al. (2010) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2010.02.008 · Cited by 85
Williamson, E. A., Wolf, I., O’Kelly, J., Bose, S., Tanosaki, S., & Koeffler, H. P. (2005) · Oncogene · doi:10.1038/sj.onc.1209170 · Cited by 79
Wang, Z., Li, M., Lu, S., et al. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.3.2380 · Cited by 74
The Fanconi Anemia/BRCA Signaling Pathway: Disruption in Cisplatin-Sensitive Ovarian Cancers
D’Andrea, A. D. (2003) · Cell Cycle · doi:10.4161/cc.2.4.413 · Cited by 65
BRCA1 transactivates the cyclin-dependent kinase inhibitor p27Kip1
Williamson, E. A., Dadmanesh, F., & Koeffler, H. P. (2002) · Oncogene · doi:10.1038/sj.onc.1205461 · Cited by 63
Xian, W., Miron, A., Roh, M. H., Semmel, D. R., Yassin, Y., Garber, J. E., Oliva, E., Goodman, A., Mehra, K. K., Berkowitz, R. S., et al. (2009) · The Journal of Pathology · doi:10.1002/path.2624 · Cited by 53
Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer
Lim, S. L., Smith, P., Syed, N., Coens, C., Wong, H. H., van der Burg, M., Szlosarek, P. W., Crook, T., & Green, J. A. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604325 · Cited by 51
Large‐scale genomic analysis of ovarian carcinomas
Gorringe, K. L., & Campbell, I. (2008) · Molecular Oncology · doi:10.1016/j.molonc.2008.12.005 · Cited by 37
Cited by
VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing
Koboldt, D. C., Zhang, Q., Larson, D. E., Shen, D., McLellan, M. D., Lin, L., Miller, C. A., Mardis, E. R., Ding, L., & Wilson, R. K. (2012) · Genome Research · doi:10.1101/gr.129684.111 · Cited by 4,905
Rethinking ovarian cancer: recommendations for improving outcomes
Vaughan, S., Coward, J. I., Bast, R. C., Berchuck, A., Berek, J. S., Brenton, J. D., Coukos, G., Crum, C. C., Drapkin, R., Etemadmoghadam, D., et al. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3144 · Cited by 1,464
Self-citationEvaluating cell lines as tumour models by comparison of genomic profiles
Domcke, S., Sinha, R., Levine, D. A., Sander, C., & Schultz, N. (2013) · Nature Communications · doi:10.1038/ncomms3126 · Cited by 1,418
Prat, J. (2012) · Virchows Archiv · doi:10.1007/s00428-012-1203-5 · Cited by 602
Latest research and treatment of advanced-stage epithelial ovarian cancer
Coleman, R. L., Monk, B. J., Sood, A. K., & Herzog, T. J. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.5 · Cited by 489
Metadata
- Authors
- Bowtell, D. D. L.
- Venue
- Nature Reviews Cancer
- Published
- 2010-10-14
- Volume
- 10
- Issue
- 11
- Pages
- 803-808
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2004144597
- Cited by
- 445
- References
- 62
- FWCI
- 5.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.